Full Press Release Details
FOR IMMEDIATE RELEASE: December
CONTACT: mindmed@150bond.com
to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing
psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel
and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics
Conference to be held on Monday, December 6, 2021.
on the panel discussion can be found below.
The Future of Mental Healthcare
Monday, December 6, 2021
webcast of the company presentation will be available on-demand through the H.C. Wainwright conference portal beginning Monday, December
6, 2021 at 7:00 a.m. ET for those registered for the event.
MindMed is a clinical-stage
psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address
addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic
substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical
experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the
Media Contact: mindmed@150bond.com
Investor Contact: bmackle@lifesciadvisors.com